Physician profile
Miranda Smith
NPI 1760529960
$9,880.84
in general payments reported to CMS, 2019-2025
24 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $891 · 2021: $1,237 · 2022: $1,492 · 2023: $1,423 · 2024: $2,009 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,088 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,087.62 |
| Education | $214.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,804.75 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $1,250.42 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $991.61 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $979.64 | 2019-2025 | Tremfya |
| Amgen INC. | $934.14 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $863.56 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $511.01 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $475.22 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $331.71 | 2019-2025 | |
| Genzyme Corporation | $281.23 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $260.02 | 2019-2025 | |
| Ucb, INC. | $259.56 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $152.36 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $142.52 | 2021-2025 | |
| Celgene Corporation | $139.79 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $103.55 | 2020-2021 | |
| Dermira, INC. | $101.66 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.16 | 2019-2020 | |
| Incyte Corporation | $73.10 | 2022-2025 | Opzelura |
| Dusa Pharmaceuticals, INC. | $48.08 | 2019 | |
| Mayne Pharma Commercial LLC | $26.59 | 2019-2020 | |
| Organon LLC | $24.09 | 2025 | Vtama, Nexplanon |
| Prugen, INC. Pharmaceuticals | $22.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.